What this Trial Is About

Researchers are investigating how the metabolome—the collection of small molecules in blood, body fluids, and tissues—differs between patients with malignant melanoma at various tumor stages and healthy individuals. The goal is to determine whether these metabolite patterns can help with early detection of melanoma diagnosis, recurrence, or changes in disease stage. This prospective, single-center study focuses on analyzing these differences over time to improve understanding of melanoma progression. Blood and other biosamples are collected and stored in the BioBank Dresden. These samples undergo analyses using Nuclear Magnetic Resonance (NMR) spectroscopy and Liquid Chromatography-Mass Spectrometry (LC-MS). The study plans to use these samples for further metabolomic analyses to explore disease-related changes. Participants are followed on average for about three years during which researchers measure differences in metabolite concentrations. The study tracks changes throughout this period to assess the metabolome's potential as an early marker for melanoma progression or recurrence. This long-term observation allows careful monitoring of metabolite patterns in relation to the disease course.

The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.